Michael Lewis is a research scientist in the Psychiatric Disease Program at the Broad Institute. He focuses on the development of animal models of psychiatric disease, as well as the molecular effects of psychiatric medication. He hopes to bring this knowledge to bear on the next generation of anti-psychotic and mood-stabilizing drugs.
In 2011, Lewis and his fellow researchers in the Broad’s Stanley Center for Psychiatric Research published a paper describing an important signaling pathway modulated by lithium — a mood-stabilizing medication used primarily in the treatment of bipolar disorder. The researchers may be able to exploit the signaling pathway to identify a new class of mood-stabilizing drugs.
Lewis joined the Broad Institute in 2008 after completing a Ph.D. in behavioral neuroscience at Temple University, and conducting postdoctoral research in the same field at Yale University.Select Publications
Pan JQ, et al. AKT Kinase Activity Is Required for Lithium to Modulate Mood-Related Behaviors in Mice. Neuropsychopharmacology. 2011 Mar 9.
Fernandez SM, et al. Estradiol-induced enhancement of object memory consolidation involves hippocampal extracellular signal-regulated kinase activation and membrane-bound estrogen receptors. J Neurosci. 2008 Aug 27;28(35):8660-7.
Fan L, et al. Estradiol-induced object memory consolidation in middle-aged female mice requires dorsal hippocampal extracellular signal-regulated kinase and phosphatidylinositol 3-kinase activation. J Neurosci. 2010 Mar 24;30(12):4390-400.